A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive
ConditionKidney Disease
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age25-55
SponsorGlaxoSmithKline
About this trial
This is a first time in Asia (FTIA) study of GSK4771261 in healthy participants of Chinese, Japanese, and White/European ancestry. The study will test whether GSK4771261 is safe, well-tolerated, how it is processed in the body, and whether it triggers an immune response.
Eligibility criteria
Qualifiers
Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and laboratory tests. A participant with a clinical abnormality or laboratory parameter(s) which is/are not specifically listed in the inclusion or
Disqualifiers
Body weight at least 50.0 kilograms (kg) for male participants or at least 45.0 kg for female participants at screening
Body Mass Index (BMI) within the range of 18.0 - 28.0 kilogram per square meters (kg/m²) (inclusive) at screening
A female participant is eligible to participate if she is not pregnant or breastfeeding, and is a Participant of non-childbearing potential (PONCBP)
Capable of giving signed informed consent
Trial design
Treatments tested in this trial
- GSK4771261
- Placebo
Treatment groups
30 Participants
are divided into 2 treatment groupsLocations
This trial has no locations
Sponsors and collaborators
GlaxoSmithKline
Lead sponsor
Source ClinicalTrials.gov